Reply to thread

Message

Testosterone and cardiovascular diseases

Several meta-analyses were subsequently published pooling data from controlled trials, mostly reporting CV safety of TT, although no definitive conclusion could be drawn because of inhomogeneity of patient population, lack of adequate statistical power, and many low-medium quality studies involved.

*On this basis, in 2018 the TRAVERSE trial was implemented, aimed at evaluating the effect of TT on MACE and efficacy measures in hypogonadal men (NCT03518034). The adequate statistical power of the trial enrolling 6,000 men will hopefully provide next year (2022) a definitive answer to the outstanding issue of CV safety of TT.

<blockquote data-quote="madman" data-source="post: 211843" data-attributes="member: 13851"><a href="https://www.excelmale.com/forum/threads/testosterone-and-cardiovascular-diseases.23993/#post-207454" target="_blank">Testosterone and cardiovascular diseases</a>Several meta-analyses were subsequently published pooling data from controlled trials, mostly reporting CV safety of TT, although no definitive conclusion could be drawn because of inhomogeneity of patient population, lack of adequate statistical power, and many low-medium quality studies involved.*On this basis, in 2018 the TRAVERSE trial was implemented, aimed at evaluating the effect of TT on MACE and efficacy measures in hypogonadal men (NCT03518034). The adequate statistical power of the trial enrolling 6,000 men will hopefully provide next year (2022) a definitive answer to the outstanding issue of CV safety of TT.</blockquote>

[QUOTE="madman, post: 211843, member: 13851"] [URL='https://www.excelmale.com/forum/threads/testosterone-and-cardiovascular-diseases.23993/#post-207454']Testosterone and cardiovascular diseases[/URL] [I]Several meta-analyses were subsequently published pooling data from controlled trials, mostly reporting CV safety of TT, [B]although no definitive conclusion could be drawn because of inhomogeneity of patient population, lack of adequate statistical power, and many low-medium quality studies involved.[/B][/I] [B][I]*On this basis, in 2018 the [U]TRAVERSE trial[/U] was implemented, aimed at evaluating the effect of TT on MACE and efficacy measures in hypogonadal men (NCT03518034). [U]The adequate statistical power of the trial enrolling 6,000 men will hopefully provide next year (2022) a definitive answer to the outstanding issue of CV safety of TT[/U].[/I][/B] [/QUOTE]

Verification

TRT Hormone Predictor Widget

Understanding Your Hormones

Estradiol (E2)

A form of estrogen produced from testosterone. Important for bone health, mood, and libido. Too high can cause side effects; too low can affect well-being.

DHT

Dihydrotestosterone is a potent androgen derived from testosterone. Affects hair growth, prostate health, and masculinization effects.

Free Testosterone

The biologically active form of testosterone not bound to proteins. Directly available for cellular uptake and biological effects.

Scientific Reference

Lakshman KM, Kaplan B, Travison TG, Basaria S, Knapp PE, Singh AB, LaValley MP, Mazer NA, Bhasin S. The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. J Clin Endocrinol Metab. 2010 Aug;95(8):3955-64.

DOI: 10.1210/jc.2010-0102 | PMID: 20534765 | PMCID: PMC2913038